A Phase I safety study of calcium release-activated calcium (CRAC) channel inhibitor CM4620 in healthy volunteers.
Latest Information Update: 24 Jan 2017
Price :
$35 *
At a glance
- Drugs Zegocractin (Primary)
- Indications Pancreatitis
- Focus Adverse reactions
- 24 Jan 2017 New trial record